fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Mycophenolate mofetil

Form:

16 of 16 products shown

14 general benefit · 2 Limited Use

CellCept · DIN 02242145 · 200 mg/mL · powder for oral suspension-175mL Pk

Limited Use, Reason for Use code 556 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 556 required
Write on scriptReason for Use code 556 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 556
Reason for Use code 556 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists CellCept (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
CellCept · DIN 02242145 Manufacturer: Hoffmann-La Roche Limited; listing date 2005-02-22 Health Canada: Marketed since 2002-08-27 · brand CELLCEPT · ATC L04AA06 MYCOPHENOLIC ACID · form Powder for suspension · route Oral · ingredients MYCOPHENOLATE MOFETIL 200 MG/ML · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242145)

Source record
DIN 02242145: CellCept Raw flags: sec12=Y, sec3=Y Item: 920000510; group id 939; item number 2236; lccId 00131; manufacturer id HLR Source form: Pd for Oral Susp-175mL Pk; strength: 200mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $358.0600; ministry $244.7025 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242145 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65823
Interchangeable products
Mar-Mycophenolate Mofetil · DIN 02522233 · $244.7025
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242145
Shortage record checked October 6, 2026

Mar-Mycophenolate Mofetil · DIN 02522233 · 200 mg/mL · powder for oral suspension-175mL Pk

Limited Use, Reason for Use code 556 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 556 required
Write on scriptReason for Use code 556 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 556
Reason for Use code 556 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Mar-Mycophenolate Mofetil · DIN 02522233 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2022-03-31 Health Canada: Marketed since 2022-02-03 · brand MAR-MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Powder for suspension · route Oral · ingredients MYCOPHENOLATE MOFETIL 200 MG/ML · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Mycophenolate Mofetil: Formulary list price $244.70 per unit (the source does not state the unit; exact figure $244.7025). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02522233)

Source record
DIN 02522233: Mar-Mycophenolate Mofetil Raw flags: sec12=Y, sec3=Y Item: 920000510; group id 939; item number 2236; lccId 00131; manufacturer id MAR Source form: Pd for Oral Susp-175mL Pk; strength: 200mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $244.7025; ministry $244.7025 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02522233 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101138
Interchangeable products
CellCept · DIN 02242145 · $244.7025
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522233
Shortage record checked October 6, 2026

CellCept · DIN 02192748 · 250 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists CellCept (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
CellCept · DIN 02192748 Manufacturer: Hoffmann-La Roche Limited; listing date 1997-04-10 Health Canada: Marketed since 1995-12-31 · brand CELLCEPT · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02192748)

Source record
DIN 02192748: CellCept Raw flags: sec3=Y Item: 920000223; group id 938; item number 2235; lccId None; manufacturer id HLR Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $2.2833; ministry $0.3712 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02192748 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19525
Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712 Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712 Mycophenolate Mofetil · DIN 02457369 · $0.3712 Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712 Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712 Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended November 12, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02192748
Shortage record checked October 6, 2026

Jamp-Mycophenolate Capsules · DIN 02386399 · 250 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Mycophenolate Capsules · DIN 02386399 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Health Canada: Marketed since 2025-10-07 · brand JAMP-MYCOPHENOLATE CAPSULES · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Mycophenolate Capsules: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3712). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02386399)

Source record
DIN 02386399: Jamp-Mycophenolate Capsules Raw flags: sec3=Y Item: 920000223; group id 938; item number 2235; lccId None; manufacturer id JPC Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.3712; ministry $0.3712 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02386399 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87198
Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712 CellCept · DIN 02192748 · $0.3712 Mycophenolate Mofetil · DIN 02457369 · $0.3712 Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712 Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712 Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended October 8, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386399
Shortage record checked October 6, 2026

Mycophenolate Mofetil · DIN 02457369 · 250 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mycophenolate Mofetil · DIN 02457369 Manufacturer: Sanis Health Inc.; listing date 2020-08-28 Health Canada: Marketed since 2016-09-29 · brand MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mycophenolate Mofetil: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3712). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457369)

Source record
DIN 02457369: Mycophenolate Mofetil Raw flags: sec3=Y Item: 920000223; group id 938; item number 2235; lccId None; manufacturer id SAI Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.3712; ministry $0.3712 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457369 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94442
Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712 CellCept · DIN 02192748 · $0.3712 Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712 Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712 Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712 Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended November 18, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457369
Shortage record checked October 6, 2026

Mycophenolate Mofetil Capsules · DIN 02383780 · 250 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mycophenolate Mofetil Capsules · DIN 02383780 Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26 Health Canada: Marketed since 2014-05-08 · brand ACH-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mycophenolate Mofetil Capsules: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3712). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02383780)

Source record
DIN 02383780: Mycophenolate Mofetil Capsules Raw flags: sec3=Y Item: 920000223; group id 938; item number 2235; lccId None; manufacturer id ACH Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.3712; ministry $0.3712 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02383780 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86955
Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712 CellCept · DIN 02192748 · $0.3712 Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712 Mycophenolate Mofetil · DIN 02457369 · $0.3712 Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712 Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended April 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02383780
Shortage record checked October 6, 2026

Sandoz Mycophenolate Mofetil · DIN 02320630 · 250 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Mycophenolate Mofetil · DIN 02320630 Manufacturer: Sandoz Canada Inc.; listing date 2012-01-19 Health Canada: Marketed since 2012-02-03 · brand SANDOZ MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Mycophenolate Mofetil: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3712). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02320630)

Source record
DIN 02320630: Sandoz Mycophenolate Mofetil Raw flags: sec3=Y Item: 920000223; group id 938; item number 2235; lccId None; manufacturer id SDZ Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.3712; ministry $0.3712 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02320630 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80604
Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712 CellCept · DIN 02192748 · $0.3712 Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712 Mycophenolate Mofetil · DIN 02457369 · $0.3712 Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712 Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: resolved shortage (ended June 16, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320630
Shortage record checked October 6, 2026

Teva-Mycophenolate · DIN 02364883 · 250 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Mycophenolate · DIN 02364883 Manufacturer: Teva Canada Limited; listing date 2012-01-19 Health Canada: Marketed since 2017-08-08 · brand TEVA-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Mycophenolate: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3712). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02364883)

Source record
DIN 02364883: Teva-Mycophenolate Raw flags: sec3=Y Item: 920000223; group id 938; item number 2235; lccId None; manufacturer id TEV Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.3712; ministry $0.3712 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364883 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84976
Interchangeable products
Apo-Mycophenolate · DIN 02352559 · $0.3712 CellCept · DIN 02192748 · $0.3712 Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712 Mycophenolate Mofetil · DIN 02457369 · $0.3712 Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712 Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712
Shortage status: active shortage (reported June 10, 2026, last updated July 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364883
Shortage record checked October 6, 2026

Ach-Mycophenolate · DIN 02378574 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Mycophenolate · DIN 02378574 Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26 Health Canada: Marketed since 2023-03-28 · brand ACH-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ach-Mycophenolate: Formulary list price $0.74 per unit (the source does not state the unit; exact figure $0.7423). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02378574)

Source record
DIN 02378574: Ach-Mycophenolate Raw flags: sec3=Y Item: 920000339; group id 940; item number 2237; lccId None; manufacturer id ACH Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7423; ministry $0.7423 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02378574 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86436
Interchangeable products
Apo-Mycophenolate · DIN 02352567 · $0.7423 CellCept · DIN 02237484 · $0.7423 Jamp-Mycophenolate · DIN 02380382 · $0.7423 Mycophenolate Mofetil · DIN 02457377 · $0.7423 Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423 Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended April 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378574
Shortage record checked October 6, 2026

CellCept · DIN 02237484 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: innoviCares lists CellCept (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
CellCept · DIN 02237484 Manufacturer: Hoffmann-La Roche Limited; listing date 2000-04-17 Health Canada: Marketed since 1998-11-11 · brand CELLCEPT · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237484)

Source record
DIN 02237484: CellCept Raw flags: sec3=Y Item: 920000339; group id 940; item number 2237; lccId None; manufacturer id HLR Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $4.5666; ministry $0.7423 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237484 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60818
Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423 Apo-Mycophenolate · DIN 02352567 · $0.7423 Jamp-Mycophenolate · DIN 02380382 · $0.7423 Mycophenolate Mofetil · DIN 02457377 · $0.7423 Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423 Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended March 12, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237484
Shortage record checked October 6, 2026

Jamp-Mycophenolate · DIN 02380382 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Mycophenolate · DIN 02380382 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Health Canada: Marketed since 2026-08-14 · brand JAMP-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Mycophenolate: Formulary list price $0.74 per unit (the source does not state the unit; exact figure $0.7423). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02380382)

Source record
DIN 02380382: Jamp-Mycophenolate Raw flags: sec3=Y Item: 920000339; group id 940; item number 2237; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7423; ministry $0.7423 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02380382 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86619
Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423 Apo-Mycophenolate · DIN 02352567 · $0.7423 CellCept · DIN 02237484 · $0.7423 Mycophenolate Mofetil · DIN 02457377 · $0.7423 Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423 Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: active shortage (reported August 7, 2025, estimated to end March 31, 2026, last updated August 9, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380382
Shortage record checked October 6, 2026

Mycophenolate Mofetil · DIN 02457377 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mycophenolate Mofetil · DIN 02457377 Manufacturer: Sanis Health Inc.; listing date 2020-08-28 Health Canada: Marketed since 2016-09-29 · brand MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mycophenolate Mofetil: Formulary list price $0.74 per unit (the source does not state the unit; exact figure $0.7423). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457377)

Source record
DIN 02457377: Mycophenolate Mofetil Raw flags: sec3=Y Item: 920000339; group id 940; item number 2237; lccId None; manufacturer id SAI Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7423; ministry $0.7423 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457377 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94443
Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423 Apo-Mycophenolate · DIN 02352567 · $0.7423 CellCept · DIN 02237484 · $0.7423 Jamp-Mycophenolate · DIN 02380382 · $0.7423 Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423 Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended February 12, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457377
Shortage record checked October 6, 2026

Sandoz Mycophenolate Mofetil · DIN 02313855 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Mycophenolate Mofetil · DIN 02313855 Manufacturer: Sandoz Canada Inc.; listing date 2012-01-19 Health Canada: Marketed since 2012-02-03 · brand SANDOZ MYCOPHENOLATE MOFETIL · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Mycophenolate Mofetil: Formulary list price $0.74 per unit (the source does not state the unit; exact figure $0.7423). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02313855)

Source record
DIN 02313855: Sandoz Mycophenolate Mofetil Raw flags: sec3=Y Item: 920000339; group id 940; item number 2237; lccId None; manufacturer id SDZ Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7423; ministry $0.7423 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02313855 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79937
Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423 Apo-Mycophenolate · DIN 02352567 · $0.7423 CellCept · DIN 02237484 · $0.7423 Jamp-Mycophenolate · DIN 02380382 · $0.7423 Mycophenolate Mofetil · DIN 02457377 · $0.7423 Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: resolved shortage (ended January 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02313855
Shortage record checked October 6, 2026

Teva-Mycophenolate · DIN 02348675 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Mycophenolate · DIN 02348675 Manufacturer: Teva Canada Limited; listing date 2012-01-19 Health Canada: Marketed since 2017-08-08 · brand TEVA-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Mycophenolate: Formulary list price $0.74 per unit (the source does not state the unit; exact figure $0.7423). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02348675)

Source record
DIN 02348675: Teva-Mycophenolate Raw flags: sec3=Y Item: 920000339; group id 940; item number 2237; lccId None; manufacturer id TEV Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7423; ministry $0.7423 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02348675 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83402
Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423 Apo-Mycophenolate · DIN 02352567 · $0.7423 CellCept · DIN 02237484 · $0.7423 Jamp-Mycophenolate · DIN 02380382 · $0.7423 Mycophenolate Mofetil · DIN 02457377 · $0.7423 Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423
Shortage status: resolved shortage (ended May 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02348675
Shortage record checked October 6, 2026

Apo-Mycophenolate · DIN 02352559 · 250 mg · capsule

General benefitDormant since June 29, 2025 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Mycophenolate · DIN 02352559 Manufacturer: Apotex Inc.; listing date 2012-01-19 Health Canada: Dormant since 2025-06-29 · brand APO-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Capsule · route Oral · ingredients MYCOPHENOLATE MOFETIL 250 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Mycophenolate: Formulary list price $0.37 per unit (the source does not state the unit; exact figure $0.3712). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02352559)

Source record
DIN 02352559: Apo-Mycophenolate Raw flags: sec3=Y Item: 920000223; group id 938; item number 2235; lccId None; manufacturer id APX Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.3712; ministry $0.3712 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352559 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83781
Interchangeable products
CellCept · DIN 02192748 · $0.3712 Jamp-Mycophenolate Capsules · DIN 02386399 · $0.3712 Mycophenolate Mofetil · DIN 02457369 · $0.3712 Mycophenolate Mofetil Capsules · DIN 02383780 · $0.3712 Sandoz Mycophenolate Mofetil · DIN 02320630 · $0.3712 Teva-Mycophenolate · DIN 02364883 · $0.3712
Shortage status: active shortage (reported December 5, 2023, last updated January 19, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352559
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since June 29, 2025 — choose a marketed DIN from the same-category list.

Apo-Mycophenolate · DIN 02352567 · 500 mg · tablet

General benefitDormant since April 18, 2025 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Mycophenolate · DIN 02352567 Manufacturer: Apotex Inc.; listing date 2012-01-19 Health Canada: Dormant since 2025-04-18 · brand APO-MYCOPHENOLATE · ATC L04AA06 MYCOPHENOLIC ACID · form Tablet · route Oral · ingredients MYCOPHENOLATE MOFETIL 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Mycophenolate: Formulary list price $0.74 per unit (the source does not state the unit; exact figure $0.7423). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02352567)

Source record
DIN 02352567: Apo-Mycophenolate Raw flags: sec3=Y Item: 920000339; group id 940; item number 2237; lccId None; manufacturer id APX Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7423; ministry $0.7423 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352567 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83782
Interchangeable products
Ach-Mycophenolate · DIN 02378574 · $0.7423 CellCept · DIN 02237484 · $0.7423 Jamp-Mycophenolate · DIN 02380382 · $0.7423 Mycophenolate Mofetil · DIN 02457377 · $0.7423 Sandoz Mycophenolate Mofetil · DIN 02313855 · $0.7423 Teva-Mycophenolate · DIN 02348675 · $0.7423
Shortage status: active shortage (reported December 5, 2023, last updated January 19, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352567
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since April 18, 2025 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (L04A, L04AA): coverage varies; not interchangeable

  • Mycophenolate (Myfortic): general benefit
  • Apremilast (Otezla): not a benefit
  • Cladribine (Mavenclad): not a benefit
  • Azathioprine (Imuran): general benefit
  • Cyclosporine (Neoral): general benefit
  • Leflunomide (Arava): general benefit

15 more in the class list below

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

MYCOPHENOLATE SODIUM

· 8 products · General benefit · strengths: 180mg, 360mg · Ent Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LENALIDOMIDE

· 42 products · Limited Use, codes 630, 631, 632, 659, 741 · strengths: 2.5mg, 15mg, 20mg, 25mg, 5mg, 10mg · Cap

SIROLIMUS

· 2 products · Limited Use, codes 392 · strengths: 1mg/mL, 1mg · O/L, Tab

TACROLIMUS

· 20 products · Limited Use, codes 173 (10), Limited Use, codes 410 (8), Limited Use, codes 383 (2) · strengths: 5mg/mL, 0.5mg, 1mg, 5mg, 3mg, 0.03%, 0.1% · Amp, Cap, ER Cap, Oint

TERIFLUNOMIDE

· 10 products · Listed, not a benefit (1), Limited Use, codes 647 (9) · strengths: 14mg · Tab

USTEKINUMAB

· 17 products · Limited Use, codes 669, 670, 671, 672 (5), Limited Use, codes 669, 671, 672, 742 (4), Limited Use, codes 668, 669, 671, 672 (2), Limited Use, codes 669, 671, 672, 733 (3), Limited Use, codes 671, 672 (3) · strengths: 45mg/0.5mL, 90mg/1.0mL, 90mg/mL, 130mg/26mL, 5mg/mL · Inj Sol-0.5mL Pref Autoinj (Preservative-Free), Inj Sol-0.5mL Pref Syr (Preservative-Free), Inj Sol-0.5mL Pref Syr Pk, Inj Sol-0.5mL Pref Syr Pk (Preservative-Free), Inj Sol-0.5mL Vial Pk, Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-1mL Pref Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr Pk, Inj Sol-26mL Vial Pk, Inj Sol-26mL Vial Pk (Preservative-Free), Inj Sol-Vial Pk (Preservative-Free)

FINGOLIMOD

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.5mg · Cap

PIRFENIDONE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 267mg · Cap

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications CellCept® (mycophenolate mofetil) is indicated for: Adults • The prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. • CellCept i.v. (mycophenolate mofetil hydrochloride for intravenous infusion) is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept i.v. should be administered within 24 hours following transplantation. CellCept i.v. can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. 1.1. Pediatrics • Pediatrics (2-18 years of age): CellCept is indicated for the prophylaxis of organ rejection in pediatric patients (2 to 18 years) receiving allogeneic renal transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. 1.2. Geriatrics • No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00083512.PDF PM date: 2026-02-11 Source product: CELLCEPT; DIN 02192748; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Mycophenolate · DIN 02364883 Shortage status: active shortage (reported 2026-06-10, last updated 2026-07-31); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364883

Check this DIN again

Jamp-Mycophenolate · DIN 02380382 Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-03-31, last updated 2025-08-09); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380382

Check this DIN again

Apo-Mycophenolate · DIN 02352559 Shortage status: active shortage (reported 2023-12-05, last updated 2024-01-19) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352559

Check this DIN again

Apo-Mycophenolate · DIN 02352567 Shortage status: active shortage (reported 2023-12-05, last updated 2024-01-19) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02352567

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)